Sudden ventricular fibrillation and death during ibrutinib therapy-A case report

Eur J Haematol. 2019 Oct;103(4):442-443. doi: 10.1111/ejh.13290. Epub 2019 Jul 22.

Abstract

Ibrutinib is an oral inhibitor of Bruton tyrosine kinase approved for the treatment of chronic lymphocytic leukaemia, mantle cell lymphoma and refractory Waldenstrom's disease. It increases progression-free survival, overall survival, response rate. The most frequent adverse reactions, are increased risk in of bleeding and atrial fibrillation, but several reports of more dangerous rhythm disturbances have been recently reported in literature. A case of a patient with refractory Waldenstrom's disease, who developed ventricular fibrillation while taking ibrutinib, is reported, along with a concise literature review.

Publication types

  • Case Reports

MeSH terms

  • Adenine / analogs & derivatives
  • Death, Sudden, Cardiac / etiology*
  • Electrocardiography
  • Humans
  • Male
  • Middle Aged
  • Piperidines
  • Protein Kinase Inhibitors / adverse effects*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles / adverse effects*
  • Pyrazoles / therapeutic use
  • Pyrimidines / adverse effects*
  • Pyrimidines / therapeutic use
  • Ventricular Fibrillation / complications*
  • Ventricular Fibrillation / diagnosis
  • Ventricular Fibrillation / etiology*
  • Waldenstrom Macroglobulinemia / complications
  • Waldenstrom Macroglobulinemia / diagnosis
  • Waldenstrom Macroglobulinemia / drug therapy

Substances

  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Adenine